Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.492 NOK
−23.82 M NOK
14.15 M NOK
About GENETIC ANALYSIS NK -,60
Sector
Industry
CEO
Ronny Hermansen
Website
Headquarters
Oslo
Founded
2008
ISIN
NO0010692130
FIGI
BBG0129CP2P9
Genetic Analysis AS develops in-vitro diagnostics tests in diseases where microbiota is involved. It is a molecular diagnostic company that provides gut microbiota analysis for testing bacterial imbalance in bowel syndrome and inflammatory bowel disease patients. The company's service products include GA-map dysbiosis test and COVID-19 fecal test and lab products include The GA-map dysbiosis test reagent kit and The COVID fecal test reagent kit. Genetic Analysis was founded in 2008 and is headquartered in Oslo, Norway.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GEAN is 0.465 NOK — it has decreased by −5.10% in the past 24 hours. Watch GENETIC ANALYSIS AS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NGM exchange GENETIC ANALYSIS AS stocks are traded under the ticker GEAN.
GEAN stock has fallen by −1.06% compared to the previous week, the month change is a 13.69% rise, over the last year GENETIC ANALYSIS AS has showed a −41.88% decrease.
GEAN reached its all-time high on Oct 6, 2021 with the price of 13.300 NOK, and its all-time low was 0.270 NOK and was reached on Apr 18, 2024. View more price dynamics on GEAN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GEAN stock is 6.52% volatile and has beta coefficient of 0.38. Track GENETIC ANALYSIS AS stock price on the chart and check out the list of the most volatile stocks — is GENETIC ANALYSIS AS there?
Today GENETIC ANALYSIS AS has the market capitalization of 22.96 M, it has decreased by −1.80% over the last week.
Yes, you can track GENETIC ANALYSIS AS financials in yearly and quarterly reports right on TradingView.
GENETIC ANALYSIS AS is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
GEAN net income for the last quarter is −3.23 M NOK, while the quarter before that showed −4.81 M NOK of net income which accounts for 32.86% change. Track more GENETIC ANALYSIS AS financial stats to get the full picture.
No, GEAN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENETIC ANALYSIS AS EBITDA is −20.98 M NOK, and current EBITDA margin is −217.41%. See more stats in GENETIC ANALYSIS AS financial statements.
Like other stocks, GEAN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENETIC ANALYSIS AS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENETIC ANALYSIS AS technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENETIC ANALYSIS AS stock shows the sell signal. See more of GENETIC ANALYSIS AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.